March 01, 2015 10:22 AM ET


Company Overview of Medicago Inc.

Company Overview

Medicago Inc., a clinical-stage biotechnology company, develops novel vaccines and therapeutic proteins to treat various infectious diseases worldwide. The company develops its vaccines based on its proprietary technologies comprising the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidates include H5N1 pandemic influenza VLP vaccine, which has completed a Phase II human clinical trial; and seasonal influenza and H1N1 vaccines. The company’s products under development also comprise non-influenza VLP and rabies vaccine candidates. It has a strategic alliance with Mitsubishi Tanabe Pharma Corporation to develop a Rotavirus vaccine candidate; and res...

1020 Route de l'Église

Suite 600

Quebec, QC G1V 3V9


Founded in 1997





Key Executives for Medicago Inc.

Chief Executive Officer, President and Director
Executive Vice President of Operations
Director of Investor Relations & Communications
Vice President of Business Development
Vice-President of Quality Assurance and Quality Control
Compensation as of Fiscal Year 2014.

Medicago Inc. Key Developments

Medicago Inc. Receives Contract by the U.S. Department of Health and Human Services to Explore Alternate Production Methods for Ebola Antibodies

Medicago Inc. announced that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services (HHS) for three anti-Ebola virus monoclonal antibodies (mAbs) with expected performance comparable to that of ZMapp, from Mapp Biopharmaceutical. Medicago will manufacture the antibodies in its Quebec City, Canada facility, for a study in non-human primates (NHP). Two of these antibodies were discovered by the Public Health Agency of Canada. This order is the result of a Task Order Request (TOR) that was solicited by BARDA on December 22, 2014. It is part of the Indefinite Delivery/Indefinite Quantity (ID/IQ) contract between Medicago and the Defense Advanced Research Projects Agency (DARPA).

Medicago Inc. Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2013

Medicago Inc. announced financial results for the second quarter and six months ended June 30, 2013. For the quarter, the company reported revenues of $918,000. Net loss was $9,073,000 or $0.04 per basic and diluted share compared to a net loss of $8,099,000 or $0.04 per basic and diluted share for the same period a year ago. For the six-months, the company reported revenues of $1,337,000. Net loss was $17,789,000 or $0.07 per basic and diluted share compared to $17,087,000 or $0.07 per basic and diluted share for the same period a year ago.

Medicago Inc. to Report Q2, 2013 Results on Aug 09, 2013

Medicago Inc. announced that they will report Q2, 2013 results After-Market on Aug 09, 2013

Similar Private Companies By Industry

Company Name Region
Toxin Alert Inc. Americas
Mikro-Tek, Inc. Americas
RegenaStem Inc. Americas
PRO-DNA Diagnostic Inc. Americas
CIHC Biodev Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Medicago Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at